Temporary decrease in tacrolimus clearance in cytochrome P450 3A5 non-expressors early after living donor kidney...

Area of Science:

• Pharmacology
• Transplantation Immunology
• Biochemistry

Background:

• Tacrolimus is a vital immunosuppressant post-kidney transplant.
• Understanding tacrolimus pharmacokinetics is crucial for optimizing patient outcomes.
• Interleukin-6 (IL-6) is implicated in inflammatory responses following transplantation.

Purpose of the Study:

• To investigate early post-kidney transplant changes in tacrolimus pharmacokinetics.
• To determine the effect of IL-6 on the expression of CYP3A4 and CYP3A5 enzymes.
• To explore the relationship between CYP3A5 expression, IL-6, and tacrolimus levels.

Main Methods:

• Historical cohort study of 22 kidney transplant recipients.
• Classification of patients into CYP3A5 expressors and non-expressors.
• In vitro experiments using HepG2 and Caco-2 cells to assess IL-6's impact on CYP3A4/CYP3A5 expression.

Main Results:

• A temporary increase in tacrolimus concentration per dose (C/D) was observed on days 3-4 post-transplant in CYP3A5 non-expressors.
• In vitro, IL-6 significantly decreased CYP3A4 and CYP3A5 expression in a concentration- and time-dependent manner.
• IL-6 reduced CYP3A4 expression to 44.0% (HepG2) and 62.6% (Caco-2), and CYP3A5 to 30.7% (HepG2) and 52.4% (Caco-2) at 12 hours.

Conclusions:

• CYP3A5 non-expressors may experience a transient reduction in tacrolimus oral clearance early post-kidney transplantation.
• Increased serum IL-6 concentrations might contribute to this pharmacokinetic alteration.
• Findings may inform strategies to enhance kidney transplant outcomes.